Semanteon Capital Management LP Makes New Investment in Henry Schein, Inc. $HSIC

Semanteon Capital Management LP acquired a new stake in Henry Schein, Inc. (NASDAQ:HSIC) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 7,829 shares of the company’s stock, valued at approximately $520,000.

Other hedge funds have also added to or reduced their stakes in the company. CW Advisors LLC lifted its position in Henry Schein by 2.8% during the 2nd quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock worth $432,000 after buying an additional 163 shares in the last quarter. Truist Financial Corp boosted its holdings in shares of Henry Schein by 3.3% in the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock valued at $368,000 after buying an additional 175 shares during the last quarter. Simon Quick Advisors LLC grew its stake in shares of Henry Schein by 5.5% in the second quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock valued at $253,000 after buying an additional 182 shares in the last quarter. Claret Asset Management Corp raised its position in Henry Schein by 6.3% during the second quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock worth $232,000 after acquiring an additional 187 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Henry Schein by 1.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after acquiring an additional 229 shares during the last quarter. Institutional investors own 96.62% of the company’s stock.

Henry Schein Trading Up 3.6%

Shares of NASDAQ:HSIC opened at $79.57 on Friday. Henry Schein, Inc. has a 12-month low of $60.56 and a 12-month high of $82.80. The business has a 50 day moving average of $77.37 and a 200-day moving average of $71.64. The company has a quick ratio of 0.79, a current ratio of 1.40 and a debt-to-equity ratio of 0.54. The stock has a market cap of $9.37 billion, a PE ratio of 25.18, a P/E/G ratio of 2.37 and a beta of 0.88.

Analysts Set New Price Targets

Several research analysts have recently weighed in on HSIC shares. Weiss Ratings restated a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Evercore boosted their price target on Henry Schein from $83.00 to $90.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 5th. Wall Street Zen upgraded Henry Schein from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. Wells Fargo & Company lifted their target price on Henry Schein from $70.00 to $76.00 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Finally, Barrington Research set a $79.00 target price on Henry Schein and gave the stock an “outperform” rating in a report on Wednesday, November 5th. Five analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $76.42.

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.